Healthcare / Diagnostics & ResearchShenzhen
$5.82
+0.06 (+1.04%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-65.7M · quality 43.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
22/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.8B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-3.5%
↓Gross Margin
45.5%
↓Debt/Equity
0.02
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-50.7%
FCF CAGR
-24.3%
FCF margin
37.2%
FCF / Net income
-1.90x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $669.6M · net income $-130.9M · FCF $249.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $669.6M | $669.6M | $815.5M | $1.10B | $5.60B |
| Net Income | $-130.9M | $-130.9M | $-654.9M | $140.5M | $1.73B |
| EBITDA | $-6.7M | $-6.7M | $-661.6M | $220.2M | $2.31B |
| EPS | -0.21 | -0.21 | -1.02 | 0.25 | 2.62 |
| Gross Margin | 45.5% | 45.5% | 47.7% | 61.0% | 69.4% |
| Operating Margin | -20.4% | -20.4% | -22.6% | 0.9% | 49.6% |
| Net Margin | -19.6% | -19.6% | -80.3% | 12.7% | 30.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.02 | 0.02 | 0.02 | 0.01 | 0.03 |
| Current Ratio | 5.38 | 5.38 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $249.2M | $249.2M | $-69.6M | $-65.7M | $574.9M |
| Returns | |||||
| ROE | -3.5% | -3.5% | -15.9% | 2.9% | 35.2% |
| Valuation | |||||
| P/E | — | — | — | 36.12 | 4.41 |
| EV/EBITDA | — | — | — | 19.83 | 2.90 |
| P/B | 0.97 | 0.97 | 0.87 | 1.04 | 1.55 |
| Growth & Yield | |||||
| Revenue Growth | -17.9% | -17.9% | -26.2% | -80.3% | — |
| EPS Growth | 79.4% | 79.4% | -508.0% | -90.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+7.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.02 → -0.21
Residual
+7.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.